<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83916">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01819649</url>
  </required_header>
  <id_info>
    <org_study_id>OUH-DK-PILOT-PRECISE</org_study_id>
    <nct_id>NCT01819649</nct_id>
  </id_info>
  <brief_title>Selenium in the Prevention of Cancer</brief_title>
  <acronym>DK PRECISE</acronym>
  <official_title>Prevention of Cancer by Intervention With Selenium - A Pilot Study in a Danish Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The K.A. Rohde and Wife Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The County of Funen, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cypress Systems, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Dagmar Marshall Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The N. O. Andersen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Directory of Food and Agriculture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Foundation of Clinical Experimental Cancer Research, Odense</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Foundation of Lily Benthine Lund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Memory Foundation of Merchant Brogaard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharma Nord</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study proceeding an intended international trial.

      Hypothesis: Daily intake of selenium supplementation in the form of selenium-enriched yeast
      tablets will reduce the risk of cancer in healthy individuals.

      Objective: The objective of this pilot study was to assess the viability of a full scale
      randomised trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Viability of full scale study</measure>
    <time_frame>At five years intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>At five years intervention (last participant last visit was june 2004) viability of full scale study was assessed according to the drop out rate, cost etc. of this pilot study.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">491</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Yeast tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S</intervention_name>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d</arm_group_label>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d</arm_group_label>
    <arm_group_label>Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  WHO performance status 0 or 1

          -  No active liver- or kidney disease (Serum ALAT (alanine aminotransferase), alkalic
             phosphatase, bilirubin, creatinin or urea within 2 S.D of laboratory reference range)

          -  No previous cancer diagnosis

          -  No known HIV-infection

          -  Participant must understand oral and written information

          -  Participant must not use selenium supplementation of above 50 mcg/d

          -  Participant must give written consent prior to inclusion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Selenium Centre, Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 26, 2013</lastchanged_date>
  <firstreceived_date>January 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>SÃ¸ren Cold</investigator_full_name>
    <investigator_title>M.D. PhD</investigator_title>
  </responsible_party>
  <keyword>selenium</keyword>
  <keyword>selenium supplementation</keyword>
  <keyword>randomised controlled trial</keyword>
  <keyword>prevention</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
